Fda Approval

Edit

Amphastar Announces FDA Approval for Ipratropium Bromide HFA

The Galveston Daily News 24 Feb 2026

Food and Drug Administration ("FDA") has approved the ...

Edit

Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock ...

Business Wire 24 Feb 2026

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former ...

Edit

Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA)

PR Newswire 24 Feb 2026

Currently no FDA-approved therapies are available for wAIHA, a rare, heterogeneous, life-threatening disease in which pathogenic immunoglobulin (IgG) autoantibodies attach to and destroy red blood cells, leading to debilitating anemia.

Edit

Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA) (Johnson & Johnson)

Public Technologies 24 Feb 2026

Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the rst-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA) ... Currently no FDA-approved therapies are ...

Edit

Vanda Pharmaceuticals (VNDA) Stock: Jumps 44% After FDA Approves Second Drug in Two Months

BitRSS 23 Feb 2026

TLDR FDA approved BYSANTI (milsaperidone) for ...

Edit

Allurion Receives U.S. FDA Approval

Rutland Herald 23 Feb 2026

NATICK, Mass.--(BUSINESS WIRE)--Feb 23, 2026-- ....

Edit

LIVE NOW: HHS Announces FDA Approval Pathway for Individualized Therapies

The Epoch Times 23 Feb 2026

The Department of Health and Human Services (HHS) announces the FDA’s approval pathway for individualized drug and biologics therapies at 11.30 a.m. ET on Feb. 23 ....

Edit

Allurion Receives U.S. FDA Approval for the Allurion Gastric Balloon System, Featuring the Allurion Smart Capsule (Form 8-K) (Allurion Technologies Holdings Inc)

Public Technologies 23 Feb 2026

FDA Approval for the Allurion Gastric Balloon System, Featuring the Allurion Smart Capsule ... Food and Drug Administration (FDA) has approved the premarket approval (PMA) application for the Allurion ...

Edit

FDA Approves VUEWAY® (gadopiclenol) Solution for Injection, Intravenous Use, for Use in Neonates and Infants

PR Newswire 23 Feb 2026

Food and Drug Administration (FDA) has approved the extension of the current VUEWAY® (gadopiclenol) solution for injection, intravenous use, for use in neonates and infants ... https.//www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022.

Edit

Vanda Pharmaceuticals Announces FDA Approval of BYSANTITM (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New Horizons in Psychiatric Innovation (Form 8-K) (Vanda Pharmaceuticals Inc)

Public Technologies 23 Feb 2026

) Vanda Pharmaceuticals Announces FDA Approval of BYSANTITM (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New Horizons in Psychiatric Innovation.

Edit

U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for ...

Hillsboro Banner 21 Feb 2026

First all-oral, fixed-duration combination regimen ...

Edit

Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder ...

Finger Lakes Times 21 Feb 2026

Food and Drug Administration (FDA) has approved ...

Edit

FDA Approves Genentech’s Venclexta® Plus Acalabrutinib Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia

The Galveston Daily News 20 Feb 2026

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Feb 20, 2026-- ....

Edit

Roche obtains FDA approval to treat chronic lymphocytic leukaemia

Swissinfo 20 Feb 2026

Genentech, a US subsidiary of Roche, has obtained approval from the United States Food and Drug Administration (FDA) for a treatment for chronic lymphocytic leukaemia (CLL) ... Translated ... .

Edit

Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New Horizons in Psychiatric Innovation (Vanda Pharmaceuticals Inc)

Public Technologies 20 Feb 2026

). The text version of this document is not available ... Disclaimer ... (noodl. 129630796) .

Podcasts:

Latest News for: fda approval

Amphastar Announces FDA Approval for Ipratropium Bromide HFA

Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock ...

Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA)

Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA) (Johnson & Johnson)

Vanda Pharmaceuticals (VNDA) Stock: Jumps 44% After FDA Approves Second Drug in Two Months

Allurion Receives U.S. FDA Approval

LIVE NOW: HHS Announces FDA Approval Pathway for Individualized Therapies

Allurion Receives U.S. FDA Approval for the Allurion Gastric Balloon System, Featuring the Allurion Smart Capsule (Form 8-K) (Allurion Technologies Holdings Inc)

FDA Approves VUEWAY® (gadopiclenol) Solution for Injection, Intravenous Use, for Use in Neonates and Infants

Vanda Pharmaceuticals Announces FDA Approval of BYSANTITM (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New Horizons in Psychiatric Innovation (Form 8-K) (Vanda Pharmaceuticals Inc)

U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for ...

Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder ...

FDA Approves Genentech’s Venclexta® Plus Acalabrutinib Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia

Roche obtains FDA approval to treat chronic lymphocytic leukaemia

Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New Horizons in Psychiatric Innovation (Vanda Pharmaceuticals Inc)

Article Search

EXPLORE WN.com